KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Net Margin (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Net Margin for 18 consecutive years, with 37.6% as the latest value for Q1 2026.

  • For Q1 2026, Net Margin rose 7405.0% year-over-year to 37.6%; the TTM value through Mar 2026 reached 2.94%, up 256.0%, while the annual FY2025 figure was 0.02%, 99.0% down from the prior year.
  • Net Margin hit 37.6% in Q1 2026 for Ionis Pharmaceuticals, down from 60.76% in the prior quarter.
  • Across five years, Net Margin topped out at 157.28% in Q4 2024 and bottomed at 119.52% in Q1 2024.
  • Average Net Margin over 5 years is 38.65%, with a median of 45.25% recorded in 2023.
  • Year-over-year, Net Margin crashed -45876bps in 2022 and then soared 16036bps in 2024.
  • Ionis Pharmaceuticals' Net Margin stood at 34.54% in 2022, then soared by 91bps to 3.08% in 2023, then skyrocketed by 5201bps to 157.28% in 2024, then crashed by -61bps to 60.76% in 2025, then plummeted by -162bps to 37.6% in 2026.
  • According to Business Quant data, Net Margin over the past three periods came in at 37.6%, 60.76%, and 82.06% for Q1 2026, Q4 2025, and Q3 2025 respectively.